Public release date: 30-Jan-2012
[ | E-mail | Share ]

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center

STANFORD, Calif. ? Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers at the Stanford University School of Medicine. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons.

The multiple successes of the direct conversion method could refute the idea that pluripotency (a term that describes the ability of stem cells to become nearly any cell in the body) is necessary for a cell to transform from one cell type to another. Together, the results raise the possibility that embryonic stem cell research and another technique called "induced pluripotency" could be supplanted by a more direct way of generating specific types of cells for therapy or research.

This new study, which will be published online Jan. 30 in the Proceedings of the National Academy of Sciences, is a substantial advance over the previous paper in that it transforms the skin cells into neural precursor cells, as opposed to neurons. While neural precursor cells can differentiate into neurons, they can also become the two other main cell types in the nervous system: astrocytes and oligodendrocytes. In addition to their greater versatility, the newly derived neural precursor cells offer another advantage over neurons because they can be cultivated to large numbers in the laboratory ? a feature critical for their long-term usefulness in transplantation or drug screening.

In the study, the switch from skin to neural precursor cells occurred with high efficiency over a period of about three weeks after the addition of just three transcription factors. (In the previous study, a different combination of three transcription factors was used to generate mature neurons.) The finding implies that it may one day be possible to generate a variety of neural-system cells for transplantation that would perfectly match a human patient.

"We are thrilled about the prospects for potential medical use of these cells," said Marius Wernig, MD, assistant professor of pathology and a member of Stanford's Institute for Stem Cell Biology and Regenerative Medicine. "We've shown the cells can integrate into a mouse brain and produce a missing protein important for the conduction of electrical signal by the neurons. This is important because the mouse model we used mimics that of a human genetic brain disease. However, more work needs to be done to generate similar cells from human skin cells and assess their safety and efficacy."

Wernig is the senior author of the research. Graduate student Ernesto Lujan is the first author.

While much research has been devoted to harnessing the pluripotency of embryonic stem cells, taking those cells from an embryo and then implanting them in a patient could prove difficult because they would not match genetically. An alternative technique involves a concept called induced pluripotency, first described in 2006. In this approach, transcription factors are added to specialized cells like those found in skin to first drive them back along the developmental timeline to an undifferentiated stem-cell-like state. These "iPS cells" are then grown under a variety of conditions to induce them to re-specialize into many different cell types.

Scientists had thought that it was necessary for a cell to first enter an induced pluripotent state or for researchers to start with an embryonic stem cell, which is pluripotent by nature, before it could go on to become a new cell type. However, research from Wernig's laboratory in early 2010 showed that it was possible to directly convert one "adult" cell type to another with the application of specialized transcription factors, a process known as transdifferentiation.

Wernig and his colleagues first converted skin cells from an adult mouse to functional neurons (which they termed induced neuronal, or iN, cells), and then replicated the feat with human cells. In 2011 they showed that they could also directly convert liver cells into iN cells.

"Dr. Wernig's demonstration that fibroblasts can be converted into functional nerve cells opens the door to consider new ways to regenerate damaged neurons using cells surrounding the area of injury," said pediatric cardiologist Deepak Srivastava, MD, who was not involved in these studies. "It also suggests that we may be able to transdifferentiate cells into other cell types." Srivastava is the director of cardiovascular research at the Gladstone Institutes at the University of California-San Francisco. In 2010, Srivastava transdifferentiated mouse heart fibroblasts into beating heart muscle cells.

"Direct conversion has a number of advantages," said Lujan. "It occurs with relatively high efficiency and it generates a fairly homogenous population of cells. In contrast, cells derived from iPS cells must be carefully screened to eliminate any remaining pluripotent cells or cells that can differentiate into different lineages." Pluripotent cells can cause cancers when transplanted into animals or humans.

The lab's previous success converting skin cells into neurons spurred Wernig and Lujan to see if they could also generate the more-versatile neural precursor cells, or NPCs. To do so, they infected embryonic mouse skin cells ? a commonly used laboratory cell line ? with a virus encoding 11 transcription factors known to be expressed at high levels in NPCs. A little more than three weeks later, they saw that about 10 percent of the cells had begun to look and act like NPCs.

Repeated experiments allowed them to winnow the original panel of 11 transcription factors to just three: Brn2, Sox2 and FoxG1. (In contrast, the conversion of skin cells directly to functional neurons requires the transcription factors Brn2, Ascl1 and Myt1l.) Skin cells expressing these three transcription factors became neural precursor cells that were able to differentiate into not just neurons and astrocytes, but also oligodendrocytes, which make the myelin that insulates nerve fibers and allows them to transmit signals. The scientists dubbed the newly converted population "induced neural precursor cells," or iNPCs.

In addition to confirming that the astrocytes, neurons and oligodendrocytes were expressing the appropriate genes and that they resembled their naturally derived peers in both shape and function when grown in the laboratory, the researchers wanted to know how the iNPCs would react when transplanted into an animal. They injected them into the brains of newborn laboratory mice bred to lack the ability to myelinate neurons. After 10 weeks, Lujan found that the cells had differentiated into oligodendroytes and had begun to coat the animals' neurons with myelin.

"Not only do these cells appear functional in the laboratory, they also seem to be able to integrate appropriately in an in vivo animal model," said Lujan.

The scientists are now working to replicate the work with skin cells from adult mice and humans, but Lujan emphasized that much more research is needed before any human transplantation experiments could be conducted. In the meantime, however, the ability to quickly and efficiently generate neural precursor cells that can be grown in the laboratory to mass quantities and maintained over time will be valuable in disease and drug-targeting studies.

"In addition to direct therapeutic application, these cells may be very useful to study human diseases in a laboratory dish or even following transplantation into a developing rodent brain," said Wernig.

###

In addition to Wernig and Lujan, other Stanford researchers involved in the study include postdoctoral scholars Soham Chanda, PhD, and Henrik Ahlenius, PhD; and professor of molecular and cellular physiology Thomas Sudhof, MD.

The research was supported by the California Institute for Regenerative Medicine, the New York Stem Cell Foundation, the Ellison Medical Foundation, the Stinehart-Reed Foundation and the National Institutes of Health.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital andamp; Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html.

PRINT MEDIA CONTACT: Krista Conger at (650) 725-5371 (kristac@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)

[ | E-mail | Share ]

andnbsp;

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read more here:
Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage

19-01-2012 22:48 Stem cell research has the potential to yield groundbreaking new tools to understand and develop therapies for CP and related brain disorders.

Here is the original post:
Professor Alan Trounson - World focus on stem cell research - Video

09-11-2011 14:00 Olga Momcilovic speaks at the 2011 CIRM Grantee Meeting about the use of induced pluripotent stem (iPS) cells to better understand the causes of Parkinson's and to develop therapies. Momcilovic is a CIRM Scholar and postdoctoral research fellow at the Buck Institute located in Novato, California.

Read more here:
Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video

Rudolf Jaenisch, MD (MIT) and recently named winner of the National Medal of Science, discussed the key issues facing the field of highly pluripotent stem cells including ES cells and iPS cells.

View post:
2011 Summit: Stem Cells, Reprogramming and Personalized Medicine, Rudolf Jaenisch, MD - Video

Interviews with Deepak Srivastava, Shinya Yamanaka and Robert Mahley on Dr. Yamanaka's discovery and future directions in stem cell research.

Read the rest here:
Advances in Stem Cell Research: Shinya Yamanaka - Video

Any cells derived from embryonic stem cells that are transplanted as a therapy will likely be rejected by the immune system much like a transplanted heart or liver. Dr. Jeffrey Bluestone has been studying ways of achieving transplantation with little or no drugs.

Follow this link:
Jeff Bluestone: Immune rejection of stem cell transplants - Video

Ian Wilmut discusses stem cell and direct cellular transformation therapy at the 2011 Stem Cell Meeting on the Mesa at the Salk Institute, Nov.

Read more:
Ian Wilmut discusses stem cell and direct cellular transformation therapy - Video

http://www.saintmaxworldwide.org A comparison of Adult stem cell research versus embryonic.

See more here:
stem cell research - Video

This video reviews the benefits of cord blood stem cells and the differences between cord blood stem cells and embryonic or adult stem cells. Cord blood stem cells have been used as a treatment for thousands of patients, while embryonic stem cells have never been used as a treatment in humans.

Continued here:
Introduction to Stem Cells - Video

Parkinson's disease is a neurodegenerative disease that affects nearly a million people in the United States. The symptoms include tremors, slow movement, muscle rigidity and less facial expression. No cure exists for the disease and current medications become less effective over time.

Follow this link:
Parkinson's Disease: Progress and Promise in Stem Cell Research - Video

(Part 5 of 6) Marius Wernig, MD, spoke at the "Spotlight on Disease Team Awards: Genetic Skin Disease," an educational event presented at the CIRM Governing Board meeting on February 4, 2010. Wernig is an assistant professor of pathology at the Institute for Stem Cell Biology and Regenerative Medicine in the Stanford School of Medicine

See the original post here:
Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video

BY STEVEN HSIEH You're watching multisource sports video news analysis from Newsy. Two injured football stars -- flying overseas for experimental, stem cell therapy

See more here:
Manning, Owens Try Stem Cell Therapy

Jeanne Loring talks about stem cells, part 3 of 3.

Go here to see the original:
Jeanne Loring talks about stem cells, part 3

Science Matters #1: Dr.

Original post:
Dr. Oz to Oprah and Michael J Fox: "The stem cell debate is dead."

http://www.CellularReprogramming.com The CellularReprogramming.com domain name is for sale! This domain is a perfect fit for any stem cell or bio-tech company specializing in iPS Cells and stem cell reprogramming. Visit us today for more information! http

Visit link:
Cellular Reprogramming Stem Cell Domain Name For Sale! - CellularReprogramming.com

http://www.juntadeandalucia.es Since its creation in November 2003, the Andalusian Stem Cell Bank has been increasing its research activity and growing at the same rate as the advances in stem cell research in national and international arenas. The Andalusian Stem Cell Bank was the first structure established in Spain specifically designed for the storage, distribution and characterization of embryonic stem cells. Having available cell lines produced under GMP standards was one of the most persistent requests of the scientific community in the field of cell therapy.

Read this article:
Andalusian Stem Cell Bank

Scripps Research Institute scientist Kristopher Nazor discusses Fragile X Syndrome, then circles back to how stem cell therapy might be able to help Fragile X and Alzheimer's patients. Talk given on Aug. 4 as part of presentation by researchers in Jeanne Loring's lab to patients with Parkinson's disease.

Read more here:
Kristopher Nazor 2

Jeanne Loring talks about stem cells, part 1. Part of meeting between Parkinson's patients and researchers in Loring's lab about the potential of induced pluripotent stem cell therapy, Aug. 4, 2011

Read the original:
Jeanne Loring talks about stem cells, part 1

(Part 4 of 6) Albert Lane, MD, spoke at the "Spotlight on Disease Team Awards: Genetic Skin Disease," an educational event presented at the CIRM Governing Board meeting on February 4, 2010. Lane is chair of the department of dermatology and professor of dermatology and pediatrics at Stanford School of Medicine.

Read the original post:
iPS Stem Cell-Based Treatment of Epidermolysis Bullosa

Dr. George Daley of Boston Children's Hospital explains the concept of Induced Pluripotent Stem Cells.

Read the original post:
IPs cells Part 1